Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHIELD-1: Vercirnon in Crohn's Disease
NCT01277666Phase 3Completed
- Sponsor
- GSK
- Start
- Dec 2010
- Primary completion
- Jul 2013
- Modality
- Small Molecules
- Countries
- 23
01
Overview
Phase 3, randomised, double-blind trial of vercirnon in Crohn's disease (3 arms), sponsored by GSK. Primary endpoint: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Response at 12 weeks. Started Dec 2010; status: completed.
02
Drugs
vercirnon
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT01277666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01277666.